Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review)
- Authors:
- Rui-Jie Ma
- Chao Ma
- Kang Hu
- Meng-Meng Zhao
- Nan Zhang
- Zhi-Gang Sun
-
Affiliations: Department of Thoracic Surgery, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, P.R. China, Research Center of Translational Medicine, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, P.R. China, Department of Breast Disease Center, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, P.R. China - Published online on: July 13, 2022 https://doi.org/10.3892/ijo.2022.5395
- Article Number: 105
-
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M and Are C: Global trends in esophageal cancer. J Surg Oncol. 115:564–579. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Huang FL and Yu SJ: Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 41:210–215. 2018. View Article : Google Scholar | |
|
Arnold M, Ferlay J, van Berge Henegouwen MI and Soerjomataram I: Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 69:1564–1571. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Maret-Ouda J, Markar SR and Lagergren J: Gastroesophageal reflux disease: A review. JAMA. 324:2536–2547. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Schlottmann F, Molena D and Patti MG: Gastroesophageal reflux and Barrett's esophagus: A pathway to esophageal adenocarcinoma. Updates Surg. 70:339–342. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Thrift AP, Shaheen NJ, Gammon MD, Bernstein L, Reid BJ, Onstad L, Risch HA, Liu G, Bird NC, Wu AH, et al: Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: A Mendelian randomization study. J Natl Cancer Inst. 106:dju2522014. View Article : Google Scholar : PubMed/NCBI | |
|
Oze I, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I, Tamakoshi A, Sasazuki S, et al: Cigarette smoking and esophageal cancer risk: An evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 42:63–73. 2012. View Article : Google Scholar | |
|
Katada C, Yokoyama T, Yano T, Kaneko K, Oda I, Shimizu Y, Doyama H, Koike T, Takizawa K, Hirao M, et al: Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology. 151:860–869.e7. 2016. View Article : Google Scholar | |
|
Mönig S, Chevallay M, Niclauss N, Zilli T, Fang W, Bansal A and Hoeppner J: Early esophageal cancer: The significance of surgery, endoscopy, and chemoradiation. Ann N Y Acad Sci. 1434:115–123. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ, Sharma NK, Chen H, Trifiletti DM and Zaorsky NG: Epidemiology of liver metastases. Cancer Epidemiol. 67:1017602020. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi N, Kohno T, Haruta S, Fujimori S, Shinohara H, Ueno M and Udagawa H: Pulmonary metastasectomy secondary to esophageal carcinoma: Long-term survival and prognostic factors. Ann Surg Oncol. 21(Suppl 3): S365–S369. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Ma W, Wu H, Wang J, Lin Y, Wang X and Zhang C: Analysis of homogeneous and heterogeneous factors for bone metastasis in esophageal cancer. Med Sci Monit. 25:9416–9425. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Carballo GB, Honorato JR, de Lopes GPF and Spohr TCLSE: A highlight on Sonic hedgehog pathway. Cell Commun Signal. 16:112018. View Article : Google Scholar : PubMed/NCBI | |
|
Vaillant C and Monard D: SHH pathway and cerebellar development. Cerebellum. 8:291–301. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Skoda AM, Simovic D, Karin V, Kardum V, Vranic S and Serman L: The role of the hedgehog signaling pathway in cancer: A comprehensive review. Bosn J Basic Med Sci. 18:8–20. 2018. View Article : Google Scholar : | |
|
Wang L, Jin JQ, Zhou Y, Tian Z, Jablons DM and He B: Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma. Oncotarget. 9:853–865. 2017. View Article : Google Scholar | |
|
Najafi M, Abbaszadegan MR, Rad A, Dastpak M, Boroumand-Noughabi S and Forghanifard MM: Crosstalk between SHH and stemness state signaling pathways in esophageal squamous cell carcinoma. J Cell Commun Signal. 11:147–153. 2017. View Article : Google Scholar : | |
|
Zhan T, Rindtorff N and Boutros M: Wnt signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : | |
|
Moghbeli M, Abbaszadegan MR, Golmakani E and Forghanifard MM: Correlation of Wnt and NOTCH pathways in esophageal squamous cell carcinoma. J Cell Commun Signal. 10:129–135. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao D, Wang B and Chen H: RAB11A mediates the proliferation and motility of esophageal cancer cells via WNT signaling pathway. Acta Biochim Pol. 67:531–538. 2020.PubMed/NCBI | |
|
Feng AL, Han X, Meng X, Chen Z, Li Q, Shu W, Dai H, Zhu J and Yang Z: PRDX2 plays an oncogenic role in esophageal squamous cell carcinoma via Wnt/β-catenin and AKT pathways. Clin Transl Oncol. 22:1838–1848. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X and Wang X: Long non-coding RNA colon cancer-associated transcript 2 may promote esophageal cancer growth and metastasis by regulating the Wnt signaling pathway. Oncol Lett. 18:1745–1754. 2019.PubMed/NCBI | |
|
Li Y, Li Y and Chen X: NOTCH and esophageal squamous cell carcinoma. Adv Exp Med Biol. 1287:59–68. 2021. View Article : Google Scholar : | |
|
Natsuizaka M, Whelan KA, Kagawa S, Tanaka K, Giroux V, Chandramouleeswaran PM, Long A, Sahu V, Darling DS, Que J, et al: Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nat Commun. 8:17582017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang T, Kee WH, Seow KT, Fung W and Cao X: The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol Cell Biol. 20:7132–7139. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Zhang T, Novotny-Diermayr V, Tan AL and Cao X: A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem. 278:29252–29260. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hu T, Yeh JE, Pinello L, Jacob J, Chakravarthy S, Yuan GC, Chopra R and Frank DA: Impact of the N-terminal domain of STAT3 in STAT3-dependent transcriptional activity. Mol Cell Biol. 35:3284–3300. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB, Wouters A, et al: The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 60:41–56. 2020. View Article : Google Scholar | |
|
Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guanizo AC, Fernando CD, Garama DJ and Gough DJ: STAT3: A multifaceted oncoprotein. Growth Factors. 36:1–14. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lim CP and Cao X: Structure, function, and regulation of STAT proteins. Mol Biosyst. 2:536–550. 2006. View Article : Google Scholar | |
|
Sgrignani J, Garofalo M, Matkovic M, Merulla J, Catapano CV and Cavalli A: Structural biology of STAT3 and Its implications for anticancer therapies development. Int J Mol Sci. 19:15912018. View Article : Google Scholar : | |
|
Hevehan DL, Miller WM and Papoutsakis ET: Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 99:1627–1637. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kato T, Sakamoto E, Kutsuna H, Kimura-Eto A, Hato F and Kitagawa S: Proteolytic conversion of STAT3alpha to STAT3gamma in human neutrophils: role of granule-derived serine proteases. J Biol Chem. 279:31076–31080. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson DE, O'Keefe RA and Grandis JR: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Chen P, Lu MS, Lin PY, Chen W and Lee K: IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. 12:262013. View Article : Google Scholar : PubMed/NCBI | |
|
Karakasheva TA, Lin EW, Tang Q, Qiao E, Waldron TJ, Soni M, Klein-Szanto AJ, Sahu V, Basu D, Ohashi S, et al: IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment. Cancer Res. 78:4957–4970. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Somasundar P, Yu AK, Vona-Davis L and McFadden DW: Differential effects of leptin on cancer in vitro. J Surg Res. 113:50–55. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Beales ILP, Garcia-Morales C, Ogunwobi OO and Mutungi G: Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol. 382:150–158. 2014. View Article : Google Scholar | |
|
Murata T, Asanuma K, Ara N, Iijima K, Hatta W, Hamada S, Asano N, Koike T, Imatani A, Masamune A and Shimosegawa T: Leptin aggravates reflux esophagitis by increasing tissue levels of macrophage migration inhibitory factor in rats. Tohoku J Exp Med. 245:45–53. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Andl CD, Mizushima T, Oyama K, Bowser M, Nakagawa H and Rustgi AK: EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am J Physiol Gastrointest Liver Physiol. 287:G1227–G1237. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bhat AA, Lu H, Soutto M, Capobianco A, Rai P, Zaika A and El-Rifai W: Exposure of Barrett's and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1. Oncogene. 37:6011–6024. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Vij N, Sharma A, Thakkar M, Sinha S and Mohan RR: PDGF-driven proliferation, migration, and IL8 chemokine secretion in human corneal fibroblasts involve JAK2-STAT3 signaling pathway. Mol Vis. 14:1020–1027. 2008.PubMed/NCBI | |
|
Wang Y, Liu S, Jiang G, Zhai W, Yang L, Li M, Chang Z and Zhu B: NOK associates with c-Src and promotes c-Src-induced STAT3 activation and cell proliferation. Cell Signal. 75:1097622020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Y, Zhang J, Zhao J, Li Z, Chen H, Qiao Y, Chen X, Liu K and Dong Z: TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3β/STAT3 signaling pathway via γ-catenin. BMC Cancer. 19:12642019. View Article : Google Scholar | |
|
Zhu J, Luo L, Tian L, Yin S, Ma X, Cheng S, Tang W, Yu J, Ma W, Zhou X, et al: Aryl hydrocarbon receptor promotes IL-10 expression in inflammatory macrophages through Src-STAT3 signaling pathway. Front Immunol. 9:20332018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Suh JM, Hwang ES, Kim DW, Chung HK, Song JH, Hwang JH, Park KC, Ro HK and Jo EK: Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: Involvement of STAT3 and suppressor of cytokine signaling. J Immunol. 171:616–627. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Jia Y, Li P, Li H, Xiao D, Wang Y and Ma X: Reciprocal activation of α5-nAChR and STAT3 in nicotine-induced human lung cancer cell proliferation. J Genet Genomics. 44:355–362. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lu R, Zhang YG and Sun J: STAT3 activation in infection and infection-associated cancer. Mol Cell Endocrinol. 451:80–87. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao X, Cao Q, Cheng Y, Zhao D, Wang Z, Yang H, Wu Q, You L, Wang Y and Lin Y: Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc Natl Acad Sci USA. 115:E2960–E2969. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kisseleva T, Bhattacharya S, Braunstein J and Schindler CW: Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 285:1–24. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Xu ZS, Zhang HX, Zhang YL, Liu TT, Ran Y, Chen LT, Wang YY and Shu HB: PASD1 promotes STAT3 activity and tumor growth by inhibiting TC45-mediated dephosphorylation of STAT3 in the nucleus. J Mol Cell Biol. 8:221–231. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu P, Zhou K, Lu S, Bai Y, Qi R and Zhang S: Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2/PGE2/STAT3 axis. J Cell Commun Signal. 14:175–192. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tong D, Liu Q, Liu G, Xu J, Lan W, Jiang Y, Xiao H, Zhang D and Jiang J: Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. Cancer Lett. 389:23–32. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Colozza G and Koo BK: Wnt/β-catenin signaling: Structure, assembly and endocytosis of the signalosome. Dev Growth Differ. 63:199–218. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mizushima T, Nakagawa H, Kamberov YG, Wilder EL, Klein PS and Rustgi AK: Wnt-1 but not epidermal growth factor induces beta-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res. 62:277–282. 2002.PubMed/NCBI | |
|
Yan S, Zhou C, Zhang W, Zhang G, Zhao X, Yang S, Wang Y, Lu N, Zhu H and Xu N: beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 271:85–97. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tuluhong D, Chen T, Wang J, Zeng H, Li H, Dunzhu W, Li Q and Wang S: FZD2 promotes TGF-β-induced epithelial-to-mesenchymal transition in breast cancer via activating notch signaling pathway. Cancer Cell Int. 21:1992021. View Article : Google Scholar | |
|
Fu Y, Zheng Q, Mao Y, Jiang X, Chen X, Liu P, Lv B, Huang T, Yang J, Cheng Y, et al: WNT2-Mediated FZD2 stabilization regulates esophageal cancer metastasis via STAT3 signaling. Front Oncol. 10:11682020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, et al: Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Gastroenterology. 142:521–530.e3. 2012. View Article : Google Scholar | |
|
Fang Y, Zhang S, Yin J, Shen YX, Wang H, Chen XS and Tang H: LINC01535 promotes proliferation and inhibits apoptosis in esophageal squamous cell cancer by activating the JAK/STAT3 pathway. Eur Rev Med Pharmacol Sci. 24:3694–3700. 2020.PubMed/NCBI | |
|
Gao J, Xia R, Chen J, Gao J, Luo X, Ke C, Ren C, Li J and Mi Y: Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2STAT3 and AKT/MDM2/p53 signaling pathways. Aging (Albany NY). 12:6240–6259. 2020. View Article : Google Scholar | |
|
Zhang R, Hao J, Guo K, Liu W, Yao F, Wu Q, Liu C, Wang Q and Yang X: Germacrone inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma cells. Biomed Res Int. 2020:76432482020.PubMed/NCBI | |
|
Cao Y, Yin X, Jia Y, Liu B, Wu S and Shang M: Plumbagin, a natural naphthoquinone, inhibits the growth of esophageal squamous cell carcinoma cells through inactivation of STAT3. Int J Mol Med. 42:1569–1576. 2018.PubMed/NCBI | |
|
Cao YY, Yu J, Liu TT, Yang KX, Yang LY, Chen Q, Shi F, Hao JJ, Cai Y and Wang MR: Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling. Cell Death Dis. 9:172018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Ye A, Wei J, Wang R and Poon K: Deoxycholic acid upregulates the reprogramming factors KFL4 and OCT4 through the IL-6/STAT3 pathway in esophageal adenocarcinoma cells. Technol Cancer Res Treat. 19:15330338209453022020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu YY, Wang WW, Huang J and Zhu WG: Ellagic acid induces esophageal squamous cell carcinoma cell apoptosis by modulating SHP-1/STAT3 signaling. Kaohsiung J Med Sci. 36:699–704. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, et al: Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 17:860–866. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bernard A, Chevrier S, Beltjens F, Dosset M, Viltard E, Lagrange A, Derangère V, Oudot A, Ghiringhelli F, Collin B, et al: Cleaved caspase-3 transcriptionally regulates angiogenesis-promoting chemotherapy resistance. Cancer Res. 79:5958–5970. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Silva KA, Dong J, Dong Y, Dong Y, Schor N, Tweardy DJ, Zhang L and Mitch WE: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem. 290:11177–11187. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JR, Wu WJ, Liu SX, Zuo LF, Wang Y, Yang JZ and Nan YM: Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway. Pathol Res Pract. 211:426–434. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mills JN, Rutkovsky AC and Giordano A: Mechanisms of resistance in estrogen receptor positive breast cancer: Overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 41:59–65. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Itami A, Shimada Y, Watanabe G and Imamura M: Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology. 57:311–317. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N, Zhang M, Wang Z, Gao W and Sun Z: Activated STAT3 could reduce survival in patients with esophageal squamous cell carcinoma by up-regulating VEGF and cyclin D1 expression. J Cancer. 11:1859–1868. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Xiao W, Ma J, Zhang Y, Li R, Ye J, Wang X, Zhong X and Wang S: Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 7:7989–7998. 2014. | |
|
Yang Y, Jin G, Liu H, Liu K, Zhao J, Chen X, Wang D, Bai R, Li X, Jang Y, et al: Metformin inhibits esophageal squamous cell carcinoma-induced angiogenesis by suppressing JAK/STAT3 signaling pathway. Oncotarget. 8:74673–74687. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, Yuan T, Zhang Y, Shi J, Bai L, Duan X, Tong R and Zhong L: AR-42: A Pan-HDAC inhibitor with antitumor and antiangiogenic activities in esophageal squamous cell carcinoma. Drug Des Devel Ther. 13:4321–4330. 2019. View Article : Google Scholar | |
|
Lei YY, Feng YF, Zeng B, Zhang W, Xu Q, Cheng F, Lan J, Luo HH, Zou JY, Chen ZG, et al: Exogenous H2S promotes cancer progression by activating JAK2/STAT3 signaling pathway in esophageal EC109 cells. Int J Clin Exp Pathol. 11:3247–3256. 2018. | |
|
Li Y, Ma J, Guo Q, Duan F, Tang F, Zheng P, Zhao Z and Lu G: Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. Dis Esophagus. 22:664–667. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xuan X, Li S, Lou X, Zheng X, Li Y, Wang F, Gao Y, Zhang H, He H and Zeng Q: Stat3 promotes invasion of esophageal squamous cell carcinoma through up-regulation of MMP2. Mol Biol Rep. 42:907–915. 2015. View Article : Google Scholar | |
|
Ou Y, Liu L, Xue L, Zhou W, Zhao Z, Xu B, Song Y and Zhan Q: TRAP1 shows clinical significance and promotes cellular migration and invasion through STAT3/MMP2 pathway in human esophageal squamous cell cancer. J Genet Genomics. 41:529–537. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Huang LSM, Snyder EY and Schooley RT: Strategies and progress in CXCR4-targeted anti-human immunodeficiency virus (HIV) therapeutic development. Clin Infect Dis. 73:919–924. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yue D, Zhang D, Shi X, Liu S, Li A, Wang D, Qin G, Ping Y, Qiao Y and Chen X: Chloroquine inhibits stemness of esophageal squamous cell carcinoma cells through targeting CXCR4-STAT3 pathway. Front Oncol. 10:3112020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu J, Gao FX, Wang C, Qin M, Han F, Xu T, Hu Z, Long Y, He XM and Deng X: IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma. J Exp Clin Cancer Res. 38:3212019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Chen X, Chen B, Chen B, Fan J, Song W, Xie Z, Jiang D, Li Q and Zhou M: Activating transcription factor 4 mediates a multidrug resistance phenotype of esophageal squamous cell carcinoma cells through transactivation of STAT3 expression. Cancer Lett. 354:142–152. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Ma K, Yang S, Zhang X, Wang F, Zhang X, Liu H and Fan Q: MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol. 53:644–658. 2018.PubMed/NCBI | |
|
Lee MC, Chen YK, Hsu YJ and Lin BR: Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. Oncol Rep. 43:549–561. 2020.PubMed/NCBI | |
|
Zang C, Liu X, Li B, He Y, Jing S, He Y, Wu W, Zhang B, Ma S and Dai W: IL-6/STAT3/TWIST inhibition reverses ionizing radiation-induced EMT and radioresistance in esophageal squamous carcinoma. Oncotarget. 8:11228–11238. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Zhang C, He J, Guo Q, Hu D, Yang X, Wang J, Kang Y, She R, Wang Z, et al: STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma. Tumour Biol. 36:2135–2142. 2015. View Article : Google Scholar | |
|
Liu Z, Wang Y, Shu S, Cai J, Tang C and Dong Z: Non-coding RNAs in kidney injury and repair. Am J Physiol Cell Physiol. 317:C177–C188. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Anastasiadou E, Jacob LS and Slack FJ: Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018. View Article : Google Scholar | |
|
Romano G, Veneziano D, Acunzo M and Croce CM: Small non-coding RNA and cancer. Carcinogenesis. 38:485–491. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Klingenberg M, Matsuda A, Diederichs S and Patel T: Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol. 67:603–618. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Simonson B and Das S: MicroRNA therapeutics: The next magic bullet? Mini Rev Med Chem. 15:467–474. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Luo X, Zhang L, Li M, Zhang W, Leng X, Zhang F, Zhao Y and Zeng X: The role of miR-125b in T lymphocytes in the pathogenesis of systemic lupus erythematosus. Clin Exp Rheumatol. 31:263–271. 2013.PubMed/NCBI | |
|
Liu LH, Li H, Li JP, Zhong H, Zhang HC, Chen J and Xiao T: miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun. 416:31–38. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu L, Deng H, Hu J, Huang S, Xiong J and Deng J: The promising role of miR-296 in human cancer. Pathol Res Pract. 214:1915–1922. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Bo X, Zheng Q, Xiao X, Wu L and Li B: miR-296 inhibits proliferation and induces apoptosis by targeting FGFR1 in human hepatocellular carcinoma. FEBS Lett. 590:4252–4262. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
He Z, Yu L, Luo S, Li M, Li J, Li Q, Sun Y and Wang C: miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4. BMC Cancer. 17:1402017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang ZZ, Luo YR, Du J, Yu Y, Yang XZ, Cui YJ and Jin XF: MiR-296-5p inhibits cell invasion and migration of esophageal squamous cell carcinoma by downregulating STAT3 signaling. Eur Rev Med Pharmacol Sci. 23:5206–5214. 2019.PubMed/NCBI | |
|
Lui WO, Pourmand N, Patterson BK and Fire A: Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 67:6031–6043. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sun QH, Yin ZX, Li Z, Tian SB, Wang HC, Zhang FX, Li LP, Zheng CN and Kong S: miR-874 inhibits gastric cancer cell proliferation by targeting SPAG9. BMC Cancer. 20:5222020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu WG, Zhuo L, Lu Y, Wang L, Ji YX and Guo Q: miR-8743p inhibits cell migration through targeting RGS4 in osteosarcoma. J Gene Med. 22:e32132020. View Article : Google Scholar | |
|
Dong D, Gong Y, Zhang D, Bao H and Gu G: miR-874 suppresses the proliferation and metastasis of osteosarcoma by targeting E2F3. Tumour Biol. 37:6447–6455. 2016. View Article : Google Scholar | |
|
Li Y, Chen X, Xue W, Liang J and Wang L: MiR-874 inhibits cell proliferation, migration, and invasion of glioma cells and correlates with prognosis of glioma patients. Neuromolecular Med. 23:247–255. 2021. View Article : Google Scholar | |
|
Xia B, Lin M, Dong W, Chen H, Li B, Zhang X, Hou Y and Lou G: Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2. J Biochem Mol Toxicol. 32:e221682018. View Article : Google Scholar : PubMed/NCBI | |
|
Feng X, Xue H, Guo S, Chen Y, Zhang X and Tang X: MiR-874-3p suppresses cell proliferation and invasion by targeting ADAM19 in nasopharyngeal carcinoma. Panminerva Med. 63:238–239. 2021. View Article : Google Scholar | |
|
Jiang B, Li Z, Zhang W, Wang H, Zhi X, Feng J, Chen Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 Inhibits cell proliferation, migration and invasion through targeting aquaporin-3 in gastric cancer. J Gastroenterol. 49:1011–1025. 2014. View Article : Google Scholar | |
|
Zhao B and Dong AS: MiR-874 inhibits cell growth and induces apoptosis by targeting STAT3 in human colorectal cancer cells. Eur Rev Med Pharmacol Sci. 20:269–277. 2016.PubMed/NCBI | |
|
Bu L, Zhang L, Tian M, Zheng Z, Tang H and Yang Q: LncRNA MIR210HG facilitates non-small cell lung cancer progression through directly regulation of miR-874/STAT3 axis. Dose Response. 18:15593258209180522020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer. Oncotarget. 6:1605–1617. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan RB, Zhang SH, He Y, Zhang XY and Zhang YB: MiR-874-3p is an independent prognostic factor and functions as an anti-oncomir in esophageal squamous cell carcinoma via targeting STAT3. Eur Rev Med Pharmacol Sci. 22:7265–7273. 2018.PubMed/NCBI | |
|
Zhang Q, Liu S, Zhang J, Ma X, Dong M, Sun B and Xin Y: Roles and regulatory mechanisms of miR-30b in cancer, cardiovascular disease, and metabolic disorders (Review). Exp Ther Med. 21:442021. View Article : Google Scholar | |
|
Meng L, Wang F, Sun S, Zheng Y, Ding Z, Sun Y, Li B, Meng Q and Xu M: MicroRNA-30b targets CBX3 and regulates cell proliferation, apoptosis, and migration in esophageal squamous cell carcinoma via the JAK2/STAT3 signaling pathway. Int J Clin Exp Pathol. 10:11828–11837. 2017.PubMed/NCBI | |
|
van Wijnen AJ, Bagheri L, Badreldin AA, Larson AN, Dudakovic A, Thaler R, Paradise CR and Wu Z: Biological functions of chromobox (CBX) proteins in stem cell self-renewal, lineage-commitment, cancer and development. Bone. 143:1156592021. View Article : Google Scholar | |
|
Xu J, Lv H, Zhang B, Xu F, Zhu H, Chen B, Zhu C and Shen J: miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma. J Thorac Dis. 11:3015–3029. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Xie Z, Li Z, Chen S and Li B: MicroRNA-613 targets FMNL2 and suppresses progression of colorectal cancer. Am J Transl Res. 8:5475–5484. 2016. | |
|
Lu Y, Tang L, Zhang Q, Zhang Z and Wei W: MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9. Artif Cells Nanomed Biotechnol. 46:980–984. 2018. View Article : Google Scholar | |
|
Luo J, Jin Y, Li M and Dong L: Tumor suppressor miR-613 induces cisplatin sensitivity in non-small cell lung cancer cells by targeting GJA1. Mol Med Rep. 23:3852021. | |
|
Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R and Huang X: MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene. 659:168–174. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Zhang H, Wang L, Zhang S and Tang M: miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1. Biochem Biophys Res Commun. 473:987–992. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Yang S, Ge W, Wang Y, Han C and Li M: MiR-613 suppressed the laryngeal squamous cell carcinoma progression through regulating PDK1. J Cell Biochem. 119:5118–5125. 2018. View Article : Google Scholar | |
|
Yang HC, Wu YH, Yen WC, Liu HY, Hwang TL, Stern A and Chiu DT: The redox role of G6PD in cell growth, cell death, and cancer. Cells. 8:10552019. View Article : Google Scholar : | |
|
Su X, Gao C, Feng X and Jiang M: miR-613 suppresses migration and invasion in esophageal squamous cell carcinoma via the targeting of G6PD. Exp Ther Med. 19:3081–3089. 2020.PubMed/NCBI | |
|
Li Z, Zhao S, Wang H, Zhang B and Zhang P: miR-4286 promotes prostate cancer progression via targeting the expression of SALL1. J Gene Med. e31272019.Epub ahead of print. PubMed/NCBI | |
|
Tsai CC, Chen TY, Tsai KJ, Lin MW, Hsu CY, Wu DC, Tsai EM and Hsieh TH: NF-κB/miR-18a-3p and miR-4286/BZRAP1 axis may mediate carcinogenesis in Helicobacter pylori-Associated gastric cancer. Biomed Pharmacother. 132:1108692020. View Article : Google Scholar | |
|
An X, Ge J, Guo H, Mi H, Zhou J, Liu Y, Weiyue and Wu Z: Overexpression of miR-4286 is an unfavorable prognostic marker in individuals with non-small cell lung cancer. J Cell Biochem. 120:17573–17583. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ho KH, Chen PH, Shih CM, Lee YT, Cheng CH, Liu AJ, Lee CC and Chen KC: miR-4286 is involved in connections between IGF-1 and TGF-β signaling for the mesenchymal transition and invasion by glioblastomas. Cell Mol Neurobiol. 42:791–806. 2020. View Article : Google Scholar | |
|
Rynkiewicz NK, Liu HJ, Balamatsias D and Mitchell CA: INPP4A/INPP4B and P-Rex proteins: Related but different? Adv Biol Regul. 52:265–279. 2012. View Article : Google Scholar | |
|
Zhang M, Tian H, Li R, Yan W and Xu R: MicroRNA-4286 promotes esophageal carcinoma development by targeting INPP4A to evoke the JAK2/STAT3 pathway activation. Pharmazie. 73:342–348. 2018.PubMed/NCBI | |
|
Ebrahimi F, Gopalan V, Smith RA and Lam AK: miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar | |
|
Zhang Z, Wang J, Cheng J and Yu X: Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells. Oncol Lett. 15:8412–8416. 2018.PubMed/NCBI | |
|
Xu J, Wang H, Wang H, Chen Q, Zhang L, Song C, Zhou Q and Hong Y: The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1. Hereditas. 156:112019. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang R, Zhang C, Liu G, Gu R and Wu H: MicroRNA-126 inhibits proliferation, migration, invasion, and EMT in osteosarcoma by targeting ZEB1. J Cell Biochem. 118:3765–3774. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Meng X and Li M: MiR-126 promotes esophageal squamous cell carcinoma via inhibition of apoptosis and autophagy. Aging (Albany NY). 12:12107–12118. 2020. View Article : Google Scholar | |
|
Indrieri A, Carrella S, Carotenuto P, Banfi S and Franco B: The pervasive role of the miR-181 family in development, neurodegeneration, and cancer. Int J Mol Sci. 21:20922020. View Article : Google Scholar : | |
|
He Y, Yang Y, Xu J, Liao Y, Liu L, Deng L and Xiong X: IL22 drives cutaneous melanoma cell proliferation, migration and invasion through activation of miR-181/STAT3/AKT axis. J Cancer. 11:2679–2687. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu DD, Zhou PJ, Wang Y, Zhang L, Fu WY, Ruan BB, Xu HP, Hu CZ, Tian L, Qin JH, et al: Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway. Mol Cancer. 15:402016. View Article : Google Scholar : PubMed/NCBI | |
|
Qian X, Zhao J, Yeung PY, Zhang QC and Kwok CK: Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci. 44:33–52. 2019. View Article : Google Scholar | |
|
Yao X, Wu L, Gu Z and Li J: LINC01535 promotes the development of osteosarcoma through modulating miR-214-3p/KCNC4 axis. Cancer Manag Res. 12:5575–5585. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Song H, Liu Y, Jin X, Liu Y, Yang Y, Li L, Wang X and Li G: Long non-coding RNA LINC01535 promotes cervical cancer progression via targeting the miR-214/EZH2 feedback loop. J Cell Mol Med. 23:6098–6111. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Jiang Q, Chen L and Chen W: LncRNA LINC01535 promotes colorectal cancer development and chemoresistance by sponging miR-761. Exp Ther Med. 22:6852021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Cao L, Wen C, Li J, Yu G and Liu C: LncRNA LINC00857 regulates lung adenocarcinoma progression, apoptosis and glycolysis by targeting miR-1179/SPAG5 axis. Hum Cell. 33:195–204. 2020. View Article : Google Scholar | |
|
Lin X, Feng D, Li P and Lv Y: LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway. Cancer Med. 9:8122–8132. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xia C, Zhang XY, Liu W, Ju M, Ju Y, Bu YZ, Wang W and Shao H: LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial-mesenchymal transition. J Cell Biochem. Dec 3–2018.Epub ahead of print. | |
|
Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J, Lu Y and Zhang J: LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma. Aging (Albany NY). 11:2812–2821. 2019. View Article : Google Scholar | |
|
Liu J, Yao L, Zhang M, Jiang J, Yang M and Wang Y: Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death. Aging (Albany NY). 11:7830–7846. 2019. View Article : Google Scholar | |
|
Liu H, Deng H, Zhao Y, Li C and Liang Y: LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 37:2792018. View Article : Google Scholar : PubMed/NCBI | |
|
Du YL, Liang Y, Cao Y, Liu L, Li J and Shi GQ: LncRNA XIST promotes migration and invasion of papillary thyroid cancer cell by modulating MiR-101-3p/CLDN1 axis. Biochem Genet. 59:437–452. 2021. View Article : Google Scholar | |
|
Zheng H, Zhang M, Ke X, Deng X, Li D and Wang Q, Yan S, Xue Y and Wang Q: LncRNA XIST/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer Biomark. 30:395–406. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Hu X, Wu Y, Cong L, He X, Lu J, Feng J and Liu D: Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression. Biomed Pharmacother. 109:2228–2236. 2019. View Article : Google Scholar | |
|
Jiang H, Deng W, Zhu K, Zeng Z, Hu B, Zhou Z, Xie A, Zhang C, Fu B, Zhou X and Wang G: LINC00467 promotes prostate cancer progression via M2 macrophage polarization and the miR-494-3p/STAT3 axis. Front Oncol. 11:6614312021. View Article : Google Scholar : | |
|
Pan L, Liang W, Fu M, Huang ZH, Li X, Zhang W, Zhang P, Qian H, Jiang PC, Xu WR and Zhang X: Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J Cancer Res Clin Oncol. 143:991–1004. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Qin X, Bian W, Li Y, Shan B, Yao Z and Li S: Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis. J Exp Clin Canc Res. 38:4772019. View Article : Google Scholar | |
|
Shi H, Liu Z, Pei D, Jiang Y, Zhu H and Chen B: Development and validation of nomogram based on lncRNA ZFAS1 for predicting survival in lymph node-negative esophageal squamous cell carcinoma patients. Oncotarget. 8:59048–59057. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Li C and Su X: Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers. J Exp Clin Cancer Res. 39:2712020. View Article : Google Scholar : PubMed/NCBI | |
|
Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, Tzou D, Yang X, Huang X, Wu J, et al: LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging (Albany NY). 11:4587–4596. 2019. View Article : Google Scholar | |
|
Li F, Zhang L and Sun Q: CircAKT3 promotes cell proliferation, survival and glutamine metabolism of gastric cancer by activating SLC1A5 expression via targeting miR-515-5p. Histol Histopathol. 37:227–241. 2022. | |
|
Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, Xu Z, Zeng A, Zhang X, Zhang X, et al: Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 18:712019. View Article : Google Scholar : PubMed/NCBI | |
|
Guan X, Chen S and Zhao Y: The role of RhoC in malignant tumor invasion, metastasis and targeted therapy. Histol Histopathol. 33:255–260. 2018. | |
|
Zang HL, Ji FJ, Ju HY and Tian XF: Circular RNA AKT3 governs malignant behaviors of esophageal cancer cells by sponging miR-17-5p. World J Gastroentero. 27:240–254. 2021. View Article : Google Scholar | |
|
Xu Z, Tie X, Li N, Yi Z, Shen F and Zhang Y: Circular RNA hsa_circ_0000654 promotes esophageal squamous cell carcinoma progression by regulating the miR-149-5p/IL-6/STAT3 pathway. IUBMB Life. 72:426–439. 2020. View Article : Google Scholar | |
|
Dilruba S and Kalayda GV: Platinum-based drugs: Past, present and future. Cancer Chemother Pharmacol. 77:1103–1124. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI | |
|
Kato H and Nakajima M: Treatments for esophageal cancer: A review. Gen Thorac Cardiovasc Surg. 61:330–335. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, Ikeda M, Takahashi-Yanaga F, Sasaguri T, Sekimoto M, Matsuura N and Monden M: Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci. 99:129–139. 2008. | |
|
Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and Fujii Y: Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu L and Chen L: Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 24:402019. View Article : Google Scholar : PubMed/NCBI | |
|
Mayanagi S, Irino T, Kawakubo H and Kitagawa Y: Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg. 3:269–275. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Wu X, Zhang F, Mo S, Lu Y, Wei W, Chen X, Lan L, Lu B and Liu Y: Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727. Oncol Rep. 37:2237–2244. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Miura M: Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 38:645–654. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, et al: Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget. 6:44675–44687. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ma L, Wei J, Su GH and Lin J: Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells. Cancer Biol Ther. 20:855–865. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M and Yuang-Chi Chang A: Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells. Oncotarget. 9:16533–16546. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Lan T, Zhang W, Dong L, Kang N, Fu M, Liu B, Liu K, Zhang C, Hou J and Zhan Q: Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways. Arch Biochem Biophys. 575:38–45. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gambacorti-Passerini C, le Coutre P and Piazza R: The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncol. 16:4395–4408. 2020. View Article : Google Scholar | |
|
Deng B, Jiang XL, Tan ZB, Cai M, Deng SH, Ding WJ, Xu YC, Wu YT, Zhang SW, Chen RX, et al: Dauricine inhibits proliferation and promotes death of melanoma cells via inhibition of Src/STAT3 signaling. Phytother Res. 35:3836–3847. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ha YNE, Dai Y, Wufuer D, Pidayi M, Anasihan G and Chen L: Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling. Neoplasma. 67:54–60. 2020. View Article : Google Scholar | |
|
Sanchez-Rangel E and Inzucchi SE: Metformin: Clinical use in type 2 diabetes. Diabetologia. 60:1586–1593. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lv Z and Guo Y: Metformin and its benefits for various diseases. Front Endocrinol (Lausanne). 11:1912020. View Article : Google Scholar | |
|
Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC and Zhang H: Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 5:e10882014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Mook RJ Jr, Premont RT and Wang J: Niclosamide: Beyond an antihelminthic drug. Cell Signal. 41:89–96. 2018. View Article : Google Scholar | |
|
Barbosa EJ, Löbenberg R, de Araujo GLB and Bou-Chacra NA: Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. Eur J Pharm Biopharm. 141:58–69. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wei W, Liu H, Yuan J and Yao Y: Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer. Fund Clin Pharmacol. 35:165–173. 2021. View Article : Google Scholar | |
|
Ferreira PMP, Sousa RWR, Ferreira JRO, Militão GCG and Bezerra DP: Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms. Pharmacol Res. 168:1055822021. View Article : Google Scholar : PubMed/NCBI | |
|
Tomeh MA, Hadianamrei R and Zhao X: A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci. 20:10332019. View Article : Google Scholar : | |
|
Zheng BZ, Liu TD, Chen G, Zhang JX and Kang X: The effect of curcumin on cell adhesion of human esophageal cancer cell. Eur Rev Med Pharmacol Sci. 22:551–560. 2018.PubMed/NCBI | |
|
Liu Y, Wang X, Zeng S, Zhang X, Zhao J, Zhang X, Chen X, Yang W, Yang Y, Dong Z, et al: The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma. J Exp Clin Canc Res. 37:3032018. View Article : Google Scholar | |
|
Wang Y, Zhou P, Qin S, Xu D, Liu Y, Fu W, Ruan B, Zhang L, Zhang Y, Wang X, et al: The curcumin analogs 2-Pyridyl cyclohexanone induce apoptosis via inhibition of the JAK2-STAT3 pathway in human esophageal squamous cell carcinoma cells. Front Pharmacol. 9:8202018. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y, Xu W, Huang Y and Zeng X: Licochalcone B, a chalcone derivative from Glycyrrhiza inflata, as a multifunctional agent for the treatment of Alzheimer's disease. Nat Prod Res. 34:736–739. 2020. View Article : Google Scholar | |
|
Song M, Yoon G, Choi JS, Kim E, Liu X, Oh HN, Chae JI, Lee MH and Shim JH: Janus kinase 2 inhibition by licochalcone B suppresses esophageal squamous cell carcinoma growth. Phytother Res. 34:2032–2043. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu YH, Wu YR, Li B and Yan ZY: Cryptotanshinone: A review of its pharmacology activities and molecular mechanisms. Fitoterapia. 145:1046332020. View Article : Google Scholar : PubMed/NCBI | |
|
Ji Y, Liu Y, Xue N, Du T, Wang L, Huang R, Li L, Yan C and Chen X: Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation. Onco Targets Ther. 12:883–896. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Imran M, Rauf A, Khan IA, Shahbaz M, Qaisrani TB, Fatmawati S, Abu-Izneid T, Imran A, Rahman KU and Gondal TA: Thymoquinone: A novel strategy to combat cancer: A review. Biomed Pharmacother. 106:390–402. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hu X, Ma J, Vikash V, Li J, Wu D, Liu Y, Zhang J and Dong W: Thymoquinone augments cisplatin-induced apoptosis on esophageal carcinoma through mitigating the activation of JAK2/STAT3 pathway. Digest Dis Sci. 63:126–134. 2018. View Article : Google Scholar | |
|
Luo YH, Li JQ, Zhang Y, Wang JR, Xu WT, Zhang Y, Feng YC, Li SZ and Jin CH: Quinalizarin induces cycle arrest and apoptosis via reactive oxygen species-mediated signaling pathways in human melanoma A375 cells. Drug Dev Res. 80:1040–1050. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zang YQ, Zhai YQ, Feng YY, Ju XY and Zuo F: Molecular mechanisms of quinalizarin induces apoptosis and G0/G1 cell cycle of human esophageal cancer HCE-4 cells depends on MAPK, STAT3, and NF-κB signaling pathways. Environ Toxicol. 36:276–286. 2021. View Article : Google Scholar | |
|
Yin Z, Zhang J, Chen L, Guo Q, Yang B, Zhang W and Kang W: Anticancer effects and mechanisms of action of plumbagin: Review of research advances. Biomed Res Int. 2020:69409532020. View Article : Google Scholar : PubMed/NCBI | |
|
Thangavel P, Puga-Olguín A, Rodríguez-Landa JF and Zepeda RC: Genistein as potential therapeutic candidate for menopausal symptoms and other related diseases. Molecules. 24:38922019. View Article : Google Scholar : | |
|
Riaz A, Rasul A, Kanwal N, Hussain G, Shah MA, Sarfraz I, Ishfaq R, Batool R, Rukhsar F and Adem Ş: Germacrone: A potent secondary metabolite with therapeutic potential in metabolic diseases, cancer and viral infections. Curr Drug Metab. 21:1079–1090. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
He C, Wang Z and Shi J: Pharmacological effects of icariin. Adv Pharmacol. 87:179–203. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gu ZF, Zhang ZT, Wang JY and Xu BB: Icariin exerts inhibitory effects on the growth and metastasis of KYSE70 human esophageal carcinoma cells via PI3K/AKT and STAT3 pathways. Environ Toxicol Phar. 54:7–13. 2017. View Article : Google Scholar | |
|
Derosa G, Maffioli P and Sahebkar A: Ellagic acid and its role in chronic diseases. Adv Exp Med Biol. 928:473–479. 2016. View Article : Google Scholar : PubMed/NCBI |
